Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
Cipla
Fuji
Colorcon
QuintilesIMS
Healthtrust
Medtronic
US Department of Justice
Baxter

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,748,573

« Back to Dashboard

Which drugs does patent 8,748,573 protect, and when does it expire?

Patent 8,748,573 protects LINZESS and is included in one NDA.

This patent has thirty-eight patent family members in twenty-three countries.
Summary for Patent: 8,748,573
Title:Formulations comprising linaclotide
Abstract: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.
Inventor(s): Fretzen; Angelika (Somerville, MA), Witowski; Steven (Melrose, MA), Grossi; Alfredo (Somerville, MA), Zhao; Hong (Somerville, MA), Dedhiya; Mahendra (Pomona, NY), Mo; Yun (Commack, NY)
Assignee: Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:12/851,330
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,748,573

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS. ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS. ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,748,573

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,802,628 Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,748,573

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Georgia, Republic of P20146209 ➤ Subscribe
Hong Kong 1161978 ➤ Subscribe
China 102186490 ➤ Subscribe
Hong Kong 1219062 ➤ Subscribe
Israel 211028 ➤ Subscribe
Japan 2012500196 ➤ Subscribe
Japan 5770629 ➤ Subscribe
Japan 2014139246 ➤ Subscribe
Japan 6034327 ➤ Subscribe
Japan 2013501071 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Citi
Harvard Business School
Federal Trade Commission
Baxter
Merck
McKesson
Fuji
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot